Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Pfizer”

A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting PneumoniaActive Not Recruiting
NCT07251465N/AUpdated Jun 22, 2026
Sponsor: Pfizer
Pneumonia
United States
A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative ColitisRecruiting
NCT06294925N/AUpdated Jun 22, 2026
Sponsor: Pfizer
Colitis, Ulcerative
Canada, Germany, United Kingdom
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian CancerRecruiting
NCT05071937Phase 2Updated Jun 18, 2026
Sponsor: Alexander B Olawaiye, MD
Ovarian Cancer · Peritoneal Cancer · Fallopian Tube Cancer
United States
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.Recruiting
NCT07219615Phase 2Updated Jun 17, 2026
Sponsor: Pfizer
Chronic Spontaneous Urticaria
United States, Bulgaria, Canada, China, Germany +5 more
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple MyelomaRecruiting
NCT06421675Phase 2Updated Jun 17, 2026
Sponsor: Ontario Clinical Oncology Group (OCOG)
Refractory Multiple Myeloma
Canada
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia AreataActive Not Recruiting
NCT07029711Phase 3Updated Jun 17, 2026
Sponsor: Pfizer
Severe Alopecia Areata
United States, China, Czechia, France, Italy +4 more
A Study of Elranatamab and Cyclophosphamide in People With Multiple MyelomaRecruiting
NCT07454382Phase 2Updated Jun 16, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Multiple Myeloma
United States
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS MutationActive Not Recruiting
NCT06106308Phase 2Updated Jun 16, 2026
Sponsor: Cardiff Oncology
Metastatic Colorectal Cancer · CRC · KRAS/NRAS Mutation
United States
Evaluation of Tumour Necrosis Factor Alpha (TNFα) Blockers in Early Rheumatoid Arthritis in FranceCompleted
NCT02927509N/AUpdated Jun 16, 2026
Sponsor: Centre Hospitalier Universitaire de Nīmes
Rheumatoid Arthritis
Evaluation of TNFα Blockers Monotherapy in Early Rheumatoid Arthritis in FranceCompleted
NCT02927535N/AUpdated Jun 16, 2026
Sponsor: Centre Hospitalier Universitaire de Nīmes
Rheumatoid Arthritis
France
Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 YearsTerminated
NCT04821310Phase 2Updated Jun 15, 2026
Sponsor: Pfizer
Esophagitis
United States, Bosnia and Herzegovina, Georgia, India, Puerto Rico +4 more
PALbociclib CoLlaborative Adjuvant StudyActive Not Recruiting
NCT02513394Phase 3Updated Jun 15, 2026
Sponsor: Alliance Foundation Trials, LLC.
Breast Cancer
United States, Australia, Austria, Belgium, Canada +16 more
Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced MalignanciesCompleted
NCT04181788Phase 1, Phase 2Updated Jun 15, 2026
Sponsor: Pfizer
Advanced Malignancies · Non-small-cell Lung Cancer
China, Japan, Russia, South Korea, Taiwan +1 more
Antibody Responses to Pneumococcal Vaccines Among HIV-infected Adults.Completed
NCT00148824Phase 2Updated Jun 15, 2026
Sponsor: ANRS, Emerging Infectious Diseases
HIV Infections
France
Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell DiseaseCompleted
NCT04255875Phase 1Updated Jun 15, 2026
Sponsor: Pfizer
Healthy · Sickle Cell Anemia
United States
Efficacy of Prazosin Versus Placebo Associated With Peg-interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe FibrosisCompleted
NCT00148837Phase 2Updated Jun 15, 2026
Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Hepatitis C, Chronic · Fibrosis
France
A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).Completed
NCT05858749N/AUpdated Jun 15, 2026
Sponsor: Pfizer
Metastatic Renal Cell Carcinoma
United States
A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy AdultsRecruiting
NCT07597928Phase 1Updated Jun 15, 2026
Sponsor: Pfizer
Healthy Adults · Healthy
United States
HEME-25: Open-Label Feasibility Study of Elranatamab Utilized in Newly Diagnosed Plasmablastic Lymphoma With or Without HIVNot Yet Recruiting
NCT07647432Phase 2, Phase 3Updated Jun 15, 2026
Sponsor: University of Illinois at Chicago
Plasmablastic Lymphoma · Hiv · Consolidation
Sunitinib Malate With Hormonal Ablation for Patients Who Will Have ProstatectomyActive Not Recruiting
NCT00329043Phase 2Updated Jun 12, 2026
Sponsor: M.D. Anderson Cancer Center
Prostate Cancer
United States
A Study About Modified RNA Vaccines Against Influenza in Healthy AdultsCompleted
NCT06436703Phase 1, Phase 2Updated Jun 12, 2026
Sponsor: Pfizer
Influenza, Human
United States
A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DMCompleted
NCT06897202Phase 2Updated Jun 12, 2026
Sponsor: Pfizer
Obesity in Diabetes · Type 2 Diabetes Mellitus (T2DM)
United States
Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)Active Not Recruiting
NCT00715442Phase 2Updated Jun 12, 2026
Sponsor: M.D. Anderson Cancer Center
Renal Cell Carcinoma
United States
The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled TrialRecruiting
NCT06439524Phase 3Updated Jun 12, 2026
Sponsor: Main Line Health
Endometriosis
United States
Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)Completed
NCT04155541N/AUpdated Jun 11, 2026
Sponsor: Pfizer
EGFR Mutation-positive Inoperable or Reccrent NSCLC
Japan

Previous page Next page